Trend Watch
“I’m Your Number One Fan”— A Clinical Look at Celebrity Worship
by Randy A. Sansone, MD, and Lori A. Sansone, MD R. Sansone is a professor in the Departments of Psychiatry and Internal Medicine at Wright State University School of Medicine in Dayton, OH, and Director of Psychiatry Education at Kettering Medical Center in Kettering, OH. L. Sansone is a civilian family medicine physician and Medical […]
A Review of New Atypical Antipsychotic Launches in the United States
by Jeff Ventimiglia, BSE; Amir H. Kalali, MD; and Leslie Citrome, MD, MPH Mr. Ventimiglia is a Senior Analyst in Clinical Development Services, Quintiles, Inc., Durham, North Carolina; Dr. Kalali is Vice President, Global Therapeutic Group Leader CNS, Quintiles, Inc., and Professor of Psychiatry, University of California, San Diego in San Diego, California; Dr. Citrome […]
An Analysis of the Intended Use of Atypical Antipsychotics in Dementia
by Jeff Ventimiglia, BSE; Amir H. Kalali, MD; Ipsit V. Vahia, MD; and Dilip V. Jeste, MD Mr. Ventimiglia is an analyst in Clinical Strategy and Solutions, Quintiles, Inc., in Durham, North Carolina; Dr. Kalali is Vice President, Global Therapeutic Group Leader CNS, Quintiles, Inc., and Professor of Psychiatry, University of California, San Diego in […]
Average Out-of-Pocket Expenses Across Different Drug Categories and Commercial Third-Party Payers
by Susan Lenderts, BA, and Amir H. Kalali, MD Ms. Lenderts is Associate Director, Global Commercial Partnering, Quintiles Commercial, Durham, North Carolina; Dr. Kalali is Vice President, Global Therapeutic Group Leader CNS, Quintiles, Inc; Professor of Psychiatry, University of California, San Diego, California. Psychiatry (Edgemont) 2010;7(10):12–13
An Analysis of the Psychiatric Pipeline
The authors explore the current state of the psychiatry drug development pipeline.
Polypharmacy of Schizophrenia
by Peter Dussias, MBA; Amir H. Kalali, MD; and Leslie Citrome, MD, MPH
Real-world Data on Atypical Antipsychotic Medication Side Effects
by Elisa Cascade; Amir H. Kalali, MD; Sagar Mehra; and Jonathan M. Meyer, MD Ms. Cascade is Vice President, Quintiles Inc./iGuard, Falls Church, Virginia; Dr. Kalali is Vice President, Global Therapeutic Group Leader CNS, Quintiles, Inc., and Professor of Psychiatry, University of California, San Diego, California; Mr. Mehra is a student intern at iGuard, Falls […]
Generic Penetration in the Retail Antidepressant Market
by Jeffrey Ventimiglia and Amir H. Kalali, MD Mr. Ventimiglia is Analyst, Strategy and Solutions, Global Customer Management, Quintiles, Inc., Durham, North Carolina; Dr. Kalali is Vice President, Global Therapeutic Group Leader CNS, Quintiles, Inc., and Professor of Psychiatry, University of California, San Diego, California. Psychiatry (Edgemont) 2010;7(6):9–11
Treatment of Fibromyalgia
by Peter Dussias; Amir H. Kalali, MD; and Roland M. Staud, MD Mr. Dussias is Executive Director, Strategic Analytics Commercial Solutions, Quintiles, Parsippany, New Jersey; Dr. Kalali is Vice President, Global Therapeutic Group Leader CNS, Quintiles, Inc., and Professor of Psychiatry, University of California, San Diego, California; and Dr. Staud is Professor of Medicine, University […]
Real-World Data on Attention Deficit Hyperactivity Disorder Medication Side Effects
by Elisa Cascade; Amir H. Kalali, MD; and Sharon B. Wigal, PhD Ms. Cascade is Vice President, Quintiles Inc./iGuard, Falls Church, Virginia; Dr. Kalali is Vice President, Global Therapeutic Group Leader CNS, Quintiles, Inc., and Professor of Psychiatry, University of California, San Diego, California; and Dr. Wigal is Clinical Professor of Pediatrics University of California; […]
